BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng F, Zhou Y, Zhou Z, Ye F, Huang B, Huang Y, Ma J, Zuo Q, Tan X, Xie J, Niu P, Wang W, Xu Y, Peng F, Zhou N, Cai C, Tang W, Xiao X, Li Y, Zhou Z, Jiang Y, Xie Y, Tan W, Gong G. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. Int J Infect Dis 2020;99:84-91. [PMID: 32758689 DOI: 10.1016/j.ijid.2020.07.053] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Jhuti D, Rawat A, Guo CM, Wilson LA, Mills EJ, Forrest JI. Interferon Treatments for SARS-CoV-2: Challenges and Opportunities. Infect Dis Ther 2022. [PMID: 35445964 DOI: 10.1007/s40121-022-00633-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Padayachee Y, Flicker S, Linton S, Cafferkey J, Kon OM, Johnston SL, Ellis AK, Desrosiers M, Turner P, Valenta R, Scadding GK. Review: The Nose as a Route for Therapy. Part 2 Immunotherapy. Front Allergy 2021;2:668781. [PMID: 35387044 DOI: 10.3389/falgy.2021.668781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vegivinti CTR, Evanson KW, Lyons H, Akosman I, Barrett A, Hardy N, Kane B, Keesari PR, Pulakurthi YS, Sheffels E, Balasubramanian P, Chibbar R, Chittajallu S, Cowie K, Karon J, Siegel L, Tarchand R, Zinn C, Gupta N, Kallmes KM, Saravu K, Touchette J. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect Dis 2022;22:107. [PMID: 35100985 DOI: 10.1186/s12879-022-07068-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
4 Al-Hajeri H, Baroun F, Abutiban F, Al-Mutairi M, Ali Y, Alawadhi A, Albasri A, Aldei A, AlEnizi A, Alhadhood N, Al-Herz A, Alkadi A, Alkanderi W, Almathkoori A, Almutairi N, Alsayegh S, Alturki A, Bahbahani H, Dehrab A, Ghanem A, Haji Hasan E, Hayat S, Saleh K, Tarakmeh H. Therapeutic role of immunomodulators during the COVID-19 pandemic - a narrative review. Postgrad Med 2022. [PMID: 35086413 DOI: 10.1080/00325481.2022.2033563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Lu L, Feng P, Yu M, Chen M, Lin AJ, Chen JL, Yu LH. Current utilization of interferon alpha for the treatment of coronavirus disease 2019: a comprehensive review. Cytokine & Growth Factor Reviews 2022. [DOI: 10.1016/j.cytogfr.2022.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Drożdżal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybyciński J, Lorzadeh S, Kotfis K, Ghavami S, Łos MJ. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat 2021;:100794. [PMID: 34991982 DOI: 10.1016/j.drup.2021.100794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
7 Córdova-Martínez A, Caballero-García A, Roche E, Noriega DC. β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19). Int J Environ Res Public Health 2021;18:12636. [PMID: 34886361 DOI: 10.3390/ijerph182312636] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Akbari A, Razmi M, Sedaghat A, Alavi Dana SMM, Amiri M, Halvani AM, Yazdani S, Sahab-Negah S. Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021. [PMID: 34694949 DOI: 10.1080/14787210.2022.1997587] [Reference Citation Analysis]
9 Okoli GN, Rabbani R, Al-Juboori A, Copstein L, Askin N, Abou-Setta AM. Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 2021;:1-12. [PMID: 34323632 DOI: 10.1080/14787210.2021.1961579] [Reference Citation Analysis]
10 Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. SARS-CoV-2 Antiviral Therapy. Clin Microbiol Rev 2021;:e0010921. [PMID: 34319150 DOI: 10.1128/CMR.00109-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
11 Honarmand K, Penn J, Agarwal A, Siemieniuk R, Brignardello-Petersen R, Bartoszko JJ, Zeraatkar D, Agoritsas T, Burns K, Fernando SM, Foroutan F, Ge L, Lamontagne F, Jimenez-Mora MA, Murthy S, Yepes-Nuñez JJ, Vandvik PO, Ye Z, Rochwerg B. Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. J Clin Epidemiol 2021;139:68-79. [PMID: 34274489 DOI: 10.1016/j.jclinepi.2021.07.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Bokharee N, Khan YH, Khokhar A, Mallhi TH, Alotaibi NH, Rasheed M. Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert Rev Anti Infect Ther 2021;:1-26. [PMID: 33719819 DOI: 10.1080/14787210.2021.1902805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang D, Chen L, Wang L, Hua F, Li J, Li Y, Zhang Y, Fan H, Li W, Clarke M. Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin. J Clin Epidemiol 2021:S0895-4356(21)00205-5. [PMID: 34224834 DOI: 10.1016/j.jclinepi.2021.06.027] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Frankel AE, Yip WC, Naik E, Hasselbalch HC. Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus. Clin Case Rep 2021;9:e04218. [PMID: 34136234 DOI: 10.1002/ccr3.4218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Fernández-Lázaro D, Fernandez-Lazaro CI, Mielgo-Ayuso J, Adams DP, García Hernández JL, González-Bernal J, González-Gross M. Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2. Front Immunol 2021;12:698672. [PMID: 34220861 DOI: 10.3389/fimmu.2021.698672] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
16 Bassetti M, Corcione S, Dettori S, Lombardi A, Lupia T, Vena A, De Rosa FG, Gori A, Giacobbe DR. Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Rev Respir Med 2021;15:985-92. [PMID: 33962524 DOI: 10.1080/17476348.2021.1927719] [Reference Citation Analysis]
17 Frankel AE, Reddy R, DeSuza KR, Deeb K, Carlin AF, Smith D, Xie Y, Naik E, Silver RT, Hasselbalch HC. Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib. Clin Case Rep 2021;9:2228-35. [PMID: 33936671 DOI: 10.1002/ccr3.3997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Park JJH, Mogg R, Smith GE, Nakimuli-Mpungu E, Jehan F, Rayner CR, Condo J, Decloedt EH, Nachega JB, Reis G, Mills EJ. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Health 2021;9:e711-20. [PMID: 33865476 DOI: 10.1016/S2214-109X(20)30542-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
19 Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health 2021;14:740-8. [PMID: 34020215 DOI: 10.1016/j.jiph.2021.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Hasselbalch HC, Skov V, Kjær L, Ellervik C, Poulsen A, Poulsen TD, Nielsen CH. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev 2021;60:28-45. [PMID: 33992887 DOI: 10.1016/j.cytogfr.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Murphy ME, Clay G, Danziger-Isakov L, Schulert G, Paulsen GC. Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics. Curr Opin Pediatr 2021;33:129-35. [PMID: 33394741 DOI: 10.1097/MOP.0000000000000983] [Reference Citation Analysis]
22 Han YJ, Lee KH, Yoon S, Nam SW, Ryu S, Seong D, Kim JS, Lee JY, Yang JW, Lee J, Koyanagi A, Hong SH, Dragioti E, Radua J, Smith L, Oh H, Ghayda RA, Kronbichler A, Effenberger M, Kresse D, Denicolò S, Kang W, Jacob L, Shin H, Shin JI. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials. Theranostics 2021;11:1207-31. [PMID: 33391531 DOI: 10.7150/thno.48342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
23 Mary A, Hénaut L, Macq PY, Badoux L, Cappe A, Porée T, Eckes M, Dupont H, Brazier M. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b-Literature Review and Personal Preliminary Experience. Front Pharmacol 2020;11:592543. [PMID: 33329000 DOI: 10.3389/fphar.2020.592543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Janapala RN, Patel J, Belfaqeeh O, Alhashmi A, Pourmand A. Novaferon, treatment in COVID-19 patients. Int J Infect Dis 2021;103:297. [PMID: 33248244 DOI: 10.1016/j.ijid.2020.11.180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Zheng F, Zhou Y, Zhou Z, Ye F, Huang B, Huang Y, Ma J, Zuo Q, Tan X, Xie J, Niu P, Wang W, Xu Y, Peng F, Zhou N, Cai C, Tang W, Xiao X, Li Y, Zhou Z, Jiang Y, Xie Y, Tan W, Gong G. Reply to "Novaferon, treatment in COVID-19 patients". Int J Infect Dis 2021;103:336-7. [PMID: 33248243 DOI: 10.1016/j.ijid.2020.11.179] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Szkaradkiewicz-Karpińska AK, Szkaradkiewicz A. Towards a more effective strategy for COVID-19 prevention (Review). Exp Ther Med 2021;21:33. [PMID: 33262819 DOI: 10.3892/etm.2020.9465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Tzou PL, Tao K, Nouhin J, Rhee SY, Hu BD, Pai S, Parkin N, Shafer RW. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. Viruses 2020;12:E1006. [PMID: 32916958 DOI: 10.3390/v12091006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
28 Kumari P, Singh A, Ngasainao MR, Shakeel I, Kumar S, Lal S, Singhal A, Sohal SS, Singh IK, Hassan MI. Potential diagnostics and therapeutic approaches in COVID-19. Clin Chim Acta 2020;510:488-97. [PMID: 32795547 DOI: 10.1016/j.cca.2020.08.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
29 Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, Pardo-Hernandez H, Qasim A, Martinez JPD, Rochwerg B, Lamontagne F, Han MA, Liu Q, Agarwal A, Agoritsas T, Chu DK, Couban R, Cusano E, Darzi A, Devji T, Fang B, Fang C, Flottorp SA, Foroutan F, Ghadimi M, Heels-Ansdell D, Honarmand K, Hou L, Hou X, Ibrahim Q, Khamis A, Lam B, Loeb M, Marcucci M, McLeod SL, Motaghi S, Murthy S, Mustafa RA, Neary JD, Rada G, Riaz IB, Sadeghirad B, Sekercioglu N, Sheng L, Sreekanta A, Switzer C, Tendal B, Thabane L, Tomlinson G, Turner T, Vandvik PO, Vernooij RW, Viteri-García A, Wang Y, Yao L, Ye Z, Guyatt GH, Brignardello-Petersen R. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020;370:m2980. [PMID: 32732190 DOI: 10.1136/bmj.m2980] [Cited by in Crossref: 196] [Cited by in F6Publishing: 318] [Article Influence: 98.0] [Reference Citation Analysis]